Loading…

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12 -receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2010-07, Vol.160 (1), p.65-72
Main Authors: Leonardi, Sergio, MD, Rao, Sunil V., MD, Harrington, Robert A., MD, Bhatt, Deepak L., MD, MPH, Gibson, C. Michael, MS, MD, Roe, Matthew T., MD, Kochman, Janusz, MD, PhD, Huber, Kurt, MD, Zeymer, Uwe, MD, Madan, Mina, MD, MHS, Gretler, Daniel D., MD, McClure, Matthew W., MD, Paynter, Gayle E., RN, BS, Thompson, Vivian, MPH, Welsh, Robert C., MD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y12 receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y12 inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel-controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2010.04.008